# Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung Cancer

> **NCT00299390** · PHASE2 · TERMINATED · sponsor: **Bayer** · enrollment: 10 (actual)

## Conditions studied

- Small Cell Lung Carcinoma

## Interventions

- **DRUG:** Sagopilone (BAY86-5302, ZK 219477)

## Key facts

- **NCT ID:** NCT00299390
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-04
- **Primary completion:** 2007-04
- **Final completion:** 2007-04
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Since only 1 of the first 10 subjects responded to the study treatment, it was decided to stop the trial due to lack of efficacy .
- **Last updated:** 2015-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00299390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00299390, "Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung Cancer". Retrieved via MORVS 2026-10-19 from https://api.morvs.ai/clinical/NCT00299390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*